Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Emergent BioSolutions (EBS) PT Raised to $71 at Chardan Capital Markets
February 22, 2019 6:47 AM ESTChardan Capital Markets analyst Keay Nakae raised the price target on Emergent BioSolutions (NYSE: EBS) to $71.00 (from $66.00) while maintaining a Buy rating.
The analyst commented, "We believe that the two recently announced acquisitions check a number of boxes that support he... More
Emergent BioSolutions (EBS) Tops Q4 EPS by 13c
February 21, 2019 4:43 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.75, $0.13 better than the analyst estimate of $0.62. Revenue for the quarter came in at $270.7 million versus the consensus estimate of $270.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More